Status:
UNKNOWN
Prebiotics in the Prevention of Necrotizing Enterocolitis
Lead Sponsor:
Shaare Zedek Medical Center
Conditions:
Necrotizing Enterocolitis
Eligibility:
All Genders
Up to 7 years
Phase:
PHASE2
Brief Summary
Necrotizing enterocolitis (NEC) is the most common gastrointestinal catastrophe affecting 10-15% of premature neonates of \<1500 gm. NEC is a disease of the immature intestine, characterized by impair...
Detailed Description
Specifically, we hope to demonstrate that fewer of the babies who are treated with galacto-oligosaccharides (GOS) will develop NEC as compared with controls. Preterm neonates, \<1750 gm birth weight ...
Eligibility Criteria
Inclusion
- Preterm neonates
- \< 1750 gm birth weight
Exclusion
- Infants who are deemed unlikely to survive
- Infants with significant congenital malformations
- Infants with other gastrointestinal problems
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2014
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT00437567
Start Date
July 1 2009
End Date
July 1 2014
Last Update
January 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaare Zedek Medical Center
Jerusalem, Israel, 91031